【摘要】 目的:观察吉西他滨(GEM)联合顺铂(DDP)、地塞米松(DXM)组成的GDP方案治疗复发性或难治性非霍奇金淋巴瘤(NHL)的疗效和毒副反应。方法:2005年10月～2007年1月我科收治的13例复发性或难治性NHL患者,分别为弥漫大B细胞淋巴瘤(BCEL-1)11例和外周T细胞淋巴瘤(TCEL-1)2例,给予吉西他滨1000mg/m2,d1、d8,静脉滴注;顺铂25mg/m2,d1～d3,静脉滴注;地塞米松20mg/d,d1～d5,口服。21天为1周期。2个周期后评价疗效,并随访疾病进展情况。结果:13例患者中,9例获缓解(69.2%),其中完全缓解4例(30.8%),部分缓解5例(38.5%)。在可随访评价的12例患者中位TTP7.9个月(95%CI:7.4～9.4个月)。毒副反应主要为骨髓抑制和轻中度的消化道反应。骨髓抑制表现为Ⅲ～Ⅳ度白细胞下降3例,Ⅲ度血小板下降4例。结论:吉西他滨联合顺铂、地塞米松组成的GDP方案治疗复发性或难治性NHL的近期疗效较好,安全性高。更多还原

【Abstract】 Objective:To evaluate the efficacy and toxicity of gemcitabine combined with cisplatin and dexamethasone in the treatment of patients with relapsed or refractory non-Hodgkin’s lymphoma.Methods:Thirteen patients with histologically confirmed relapsed or refractory non-Hodgkin’s lymphoma were enrolled in this study.The chemotherapy regimen consisted gemcitabine(1g/m2,days 1 and 8),cisplatin(25mg/m2,day 1-3) and dexamethasone(20mg/d,day 1-5) given every three weeks,every patients received at least for 2 cycles.Results:Of 13 patients,9 patients(69.2%) showed response including 4 patients(30.8%) having complete response and 5 patients(38.5%) partial response.The median time to progression of disease for twelve patients that were received the follow-up was 7.9 months(95%CI:7.4-9.4 months).Drug related toxic effects were mild gastrointestinal reactions in most patients as well as mild bone marrow depression in some patients such as neutropenia,thrombocytopenia.Conclusion:The combination of gemcitabine,cisplatin and dexamethasone possesses better short-term efficacy,acceptable toxicity,and obvious alleviation of symptoms related to the disease.This protocol is worthy to be warranted as salvage for relapsed or refractory non-Hodgkin’s lymphoma.更多还原